Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorMayo Clinic
About this trial
single-center, randomized, double-blind, placebo-controlled Phase 2 study to evaluate safety and efficacy of overnight metyrapone in patients with MACS.
Eligibility criteria
Qualifiers
Provide written informed consent.
Stated willingness to comply with all study procedures and availability for the duration of the study.
Age ≥ 18 years
Diagnosed with MACS i. at least 2 abnormal post-dexamethasone cortisol results1 mg post-dexamethasone cortisol >1.8 mcg/dL or ii. 8 mg post-dexamethasone cortisol >1 mcg/dL b. Historical dexamethasone suppression test results can be used if performed within 24 months prior to enrollment.
Disqualifiers
Planned alternative therapy for MACS within 12 months after joining the study.
Current use of oral exogenous glucocorticoid therapy
Current use of opioid therapy >20 MME/day
Planned use of oral exogenous glucocorticoid therapy
Trial design
Treatments tested in this trial
- Metyrapone 250 mg Oral Tablets
- Placebo
Treatment groups
90 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov